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The loss of heterozygosity (LOH) is a genetic event that can change gene 
function. FHIT is a potential tumor suppressor gene. Although the precise 
FHIT molecular mechanism of action is not well understood, evidences 
suggest that Fhit protein reduced levels are involved in mammary 
carcinogenesis. The aim of this study was to investigate if FHIT LOH could 
influence on sporadic breast cancer (BC) biological behavior, through its 
association with prognostic factors for sporadic BC. 
Tumor tissue and peripheral blood samples were analyzed using the 
microsatellite marker D3S1300. The findings were associated with 
clinicopathological parameters including overall survival. LOH was 
detected in 31.1%(52/167) of the informative BC’ cases. Considering 
clinical and pathological characteristics we have found no significant 
association with FHIT LOH status. The mean follow-up time was 80 
months. After the Cox regression analysis two parameters remained 
associated with BC’s risk of death: TNM stage III and IV - HR = 3.74(95% 
CI, 1.16-12.1) P=0.027 and disease relapse HR = 3.14(CI 95% 1.26-7.80) P 
=0.014. 
This study shows that FHIT LOH by itself is not a prognostic factor for 
sporadic BC. Further researches are required to elucidate the functional role 








Breast cancer remains the most common cause of can-
cer-related deaths in women globally [1].
Innumerous are the efforts to find and understand the 
set of genetic and epigenetic changes that can influence 
mammary carcinogenesis and tumor biological behavior [2]. 
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Over the last years, advanced molecular techniques have 
brought to the research front opportunities to investigate 
new biomarkers for BC [2-3].
The FHIT gene is located on chromosome 3p14.2, en-
compassing the most common fragile site of the human 
genome, the FRA3B. The degree of fragility at this site 
may provide greater susceptibility to chromosomal rear-
rangements, allelic losses and breaks: alterations frequent-
ly observed in neoplastic cells [4].
Although FHIT function is not completely understood, 
this gene is considered a potential tumor suppressor. It 
has been involved in the pathogenesis of several tumors, 
including BC [5].
The loss of heterozygosis (LOH) is a genetic change 
commonly observed in human cancers. It occurs when a 
chromosomal region is lost, leading to changes in the gene 
function [6].
Regarding to BC the role of FHIT LOH is still on de-
bate. Ahmadian et al. [7] inferred that FHIT LOH would be 
an early but not independent event in BC’s carcinogenesis. 
De Oliveira et al. [8] have shown an association between 
FHIT LOH and ductal BC subtype. While Santos et al. [9]
ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ found no connections between BC‘s 
clinical features and FHIT LOH. Considering the potential 
of FHIT LOH as a prognostic factor for BC, only Ingvars-
son et al. [10] reported a relationship between FHIT LOH 
and patient’s survival. 
In this sense, our study aimed to analyze FHIT LOH 
in a cohort of BC’s patients and to investigate its possible 
association with clinical pathological factors and survival.
2. Materials and Methods
2.1 Study Population
The study sample was composed by paired tumor tissue 
and blood samples from 214 female patients diagnosed 
with sporadic breast cancer, from 2009 to 2014, at the 
Mastology Clinic of Femina Hospital, a reference women 
hospital in Southern Brazil.
Patients with proliferative mammary disorders, history 
of other types of cancer and male patients were excluded 
from the study.
According to the study protocol, all patients were eval-
uated on pre-operatory period to diagnose and stage the 
disease. Clinical and pathological data were filled in a 
standardized form. Data regarding to pathological charac-
teristics were collected from pathology reports. 
Tumor stage was established according to AJCC (2017). 
2.2 Collection of Peripheral Blood and Tumor 
Tissue
Peripheral blood samples were collected by intravenous 
puncture. About 10 ml of peripheral blood in sterile tubes 
containing anticoagulant were collected from each patient.
Samples of the tumor tissue were obtained during the 
surgical procedure to treat the disease. Tumor samples 
were prepared for frozen sections, to check if there was 
sufficient amount of tumor to emit a reliable signal in the 
LOH analysis.
The blood and tumor tissue were packaged in sterile 
tubes and stored at -80ºC for later DNA extraction.
2.3 Procedures
Genomic DNA was extracted from the samples: tumor 
tissue and blood sample, using PureLinkTMGenomic DNA 
Mini Kit (InvitrogenTM, Carlsbad, CA, USA), following 
manufacturer’s instructions (Invitrogen Kit Handbook). In 
all the samples, the quality measurement of the extraction 
product was determined by spectrophotometry (Nano-
Drop).
Polymerase chain reaction (PCR) was used to amplify 
the microsatellite marker D3S1300, located within FHIT 
gene (intron 5). The primers were constructed according to 
the information of reference [11] AGCTCACATTCTAGT-
CAGCCT/GCCAATTCCCCAGATG and forward primer 
was labeled fluorescent dye 6-FAM. 
The reactions were prepared to a final volume of 15 uL, 
containing 0.5 uL of genomic DNA, PCR buffer 1X, 1.5 
mM MgCl2 , 200 µM of dNTPs, 750 nM of each pair of 
primer and 1,0 unit of platinum Taq DNA polymerase (In-
vitrogen TM, Carlsbad, CA, USA). Each microsatellite was 
amplified using genomic DNA (tumoral tissue and blood 
samples), after initial denaturation during 5 minutes at 
96°C, were realized 35 cycles of the following stages: de-
naturation at 96°C for 30 seconds, annealing ate 55°C for 
30 seconds and extension at 72°C for 1 minutes, followed 
by a final extension at 72°C for 20 minutes. 
2.4 LOH Analysis
To verify its specificity and approximate concentration, 
the PCR products were analyzed by electrophoresis in 
agarose 1% gel stained with ethidium bromide and visual-
ized under UV translluminator.
PCR product (1 µL) was added and homogenized with 
to 8.5 µL of formamide HiDi (Applied Biosystems, Foster 
City, CA, USA) and 0.5 of GeneScan 500 LIZTM (Applied 
Biosystems, Foster City, CA, USA). Samples were dena-
turized for 5 minutes at 95°C and subsequently evaluated 
by capillary electrophoresis on ABI-PRISM 3130 (Applied 
BiosystemsTM, Foster City, CA, USA). The results were 
analyzed by the software GeneMapperTM, version 4.0 (Ap-
plied BiosystemsTM, Foster City, CA, USA). 
DOI: https://doi.org/10.30564/jor.v3i2.3632
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LOH was calculated as described by Van Houten et al. 
[12]. We considered LOH when we had a ratio score <0.67 
or >1.35. Homozygote cases, or those with unclear results, 
due stutter or artifacts, were considered as non-informa-
tive (NI). Values between 0.67 and 1.35 were considered 
normal heterozygotes. 
2.5 Statistical Analysis
Data were presented as frequency and percentage or 
mean ± standard deviation (SD). We performed associa-
tions between variables with the Fisher's exact test. For 
comparing continuous variables, a Student t test or an 
unequal variance t test was used. Kaplan-Meier curves for 
cumulative survival were compared using log rank test. 
Survival analysis was performed by Cox proportional haz-
ard regression models: (i) events were defined as the time 
to death; (ii) censored data were used when the event did 
not occur at the end of the follow up period. All parame-
ters associated with death (P less than 0.1) in univariate 
analysis were included in a multivariate model and con-
sidered statistically significant if the overall P value was 
less than 0.05. Models were adjusted all variables. The 
analysis supported the assumption of proportional hazard. 
Data were analyzed using Stata software, version 13 (Stat-
aCorp, College Station, TX, USA).
3. Results
From the total of 214 enrolled patients, 47 (22.0%) 
were homozygotes, non-informative (NI) cases, being ex-
cluded from the study. FHIT LOH was found in 52 (31.1%) 
of 167 heterozygotes, informative cases.
Considering clinical and pathological characteristics, 
FHIT LOH status did not present significant association 
with age, tumor size and grade, TNM stage, vascular in-
vasion, estrogenic receptors status, Ki67 index, molecular 
phenotype and neoadjuvant chemotherapy (supplementary 
table).
Regarding the survival analysis, the mean follow-up 
time was 80 months (min. 4 - max. 96 months). During 
this time 33 (19.8%) patients died from BC. Since both 
groups (FHIT LOH present and absent) had homogenous 
clinical data, we performed a Cox regression analysis in 
order to investigate the role of FHIT LOH on patients’ sur-
vival. After the multivariate analysis, only two parameters 
remained associated with risk of death: TNM stage III and 
IV – HR = 3.74 (CI 95% 1.16-12.1) P = 0.027 and disease 
relapse HR = 3.14 (CI 95% 1.26-7.80) P = 0.014 denoted 
in Table 1. Thus, as we can see in the Kaplan-Meier curve, 
FHIT LOH had no impact on patients’ overall survival 
(Figure 1).
Table 1. Cox regression analysis for overall mortality.
Variables
Univariate analysis Multivariate analysisa-b
HR (CI 95%) P HR (CI 95%) P
LOH 1.40 (0.67-2.92) <0.360
Age, years 1.03 (0.99-1.07) <0.067 1.01 (0.98-1.05) <0.216




Histological type, lobular 1.33 (0.47-3.70) <0.582
TNM stage, III-IV 9.06 (3.78-21.6) <0.001 3.74 (1.16-12.1) <0.027
Vascular invasion 3.18 (1.41-7.15) <0.005 1.03 (0.38-2.80) <0.942
Molecular phenotype <0.012 <0.647
Luminal B 2.39 (0.81-6.98) 1.58 (0.36-6.77)
HER2 6.23 (1.68-23.1) 2.57 (0.44-14.7)
Triple negative 3.70 (1.13-12.1) 2.21 (0.60-8.11)
Estrogenic receptor, positive 0.41 (0.20-0.84) <0.015 0.85 (0.17-4.23) 0.852
Ki67, >14% 1.53 (0.73-3.23) <0.256
Neoadjuvant chemotherapy 1.58 (0.79-3.14) <0.193
Disease relapse 7.88 (3.87-16.0) <0.001 3.14 (1.26-7.80) <0.014
Abbreviations: FHIT, fragile histidine triad; HR, hazard ratio; LOH, loss of heterozygosis. CI, confidence interval.
a Included in a multivariate model variables p value was less than 0.1.
b HR adjusted for age, tumour size, TNM stage, vascular invasion, molecular phenotype, estrogenic receptor and disease relapse.
DOI: https://doi.org/10.30564/jor.v3i2.3632
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Figure 1. FHIT LOH status and patients’ overall survival 
time.
4. Discussion 
The precise molecular action mechanism of FHIT gene 
is still unclear, but progress is focused on understanding 
FHIT function related to tumor suppression [13-14].
Studies have pointed out that low levels of Fhit protein 
could be related with unfavorable parameters in BC [15-17].
LOH at the FHIT gene appears to disrupt its function, 
leading to a reduction in the gene transcripts [7,17].
In the present study, we intended to investigate if the 
frequency of FHIT LOH could influence on tumor biolog-
ical behavior, through its association with prognostic and 
predictive factors in sporadic BC’s cases.
In our study, the frequency of LOH at the FHIT gene 
detected by the intragenic marker D3S1300 was 31.1% 
(52 out of 167 informative cases). According to previous 
published data, FHIT LOH frequencies range from 24% 
to 45%, considering different BC’s populations [8-9,11,18-20].
We decided to use the marker D3S1300 because it was 
able to detect high levels of FHIT LOH in prior studies [8-
9,11,18,20].
Considering the clinical and pathological variables 
studied we found no significant association between them 
and FHIT LOH status. Similar results were also reported 
by Man et al. [19] studying low grade BC. Despite the LOH 
frequency of 40% detected by the marker D3S1300, no as-
sociation was observed regarding age, tumor size, lymph 
node stage, presence of vascular invasion, menopausal 
status, and estrogenic receptor status. Also Santos et al. [9] 
showed no correlation of FHIT LOH and tumor size and 
grade, and axillary metastases. However, the authors high-
lighted the fact that from the six cases with LOH at the 
intragenic marker D3S1300, four had also BRCA1 LOH 
and suggested that the losses at these genes could be cor-
related. Subsequently the same group of researchers ana-
lyzed 3 markers for each gene LOH: FHIT and BRCA1 in 
BC’s patients and found significant clinical and prognostic 
association only in the cases with concomitant LOH in 
both genes. When the LOH was observed exclusively in 
one of the two genes it had none clinical impact [20]. The 
idea of simultaneous LOH at distinct chromosome sites is 
not new. It was demonstrated by Ingvarsson et al. [10] an 
association of FHIT LOH and the presence of LOH at oth-
er 12 chromosome regions. We should also keep in mind 
that FHIT is located in an active fragile site, the FRA3B. 
Because of its genomic instability, genetic alterations in 
other genomic sites could influence on it, predisposing to 
losses and breaks [14,16,21]. It is also in consonance with the 
concept of multistep carcinogenesis, in which cancer re-
sults from an accumulation of mutations [22].
Few studies analyzed FHIT locus changes and patient 
survival. Some of these use distinctive methodologies and 
included various tumors types, such as cervical, lung, co-
lon, and gastric cancers [23-25]. When it comes to the LOH 
at FHIT gene and BC´s patients’ survival, studies are re-
stricted to two.
Silva Soares et al. [20] have shown reduced survival 
time after 48 months of follow-up of 72 BC’s patients 
who have concurrent BRCA1 and FHIT LOH (P=0.04). 
Patients with FHIT LOH alone had no differences regard-
ing to survival time. The other study including patients’ 
survival analysis enrolled 239 women with BC. After a 
mean follow-up time of 5 years the authors reported a 
relative risk of dying for patients with FHIT LOH of 1.6 
(95% CI: 1.0-2.6) P=0.45. [10] However, despite the effect 
of FHIT LOH on patients’ survival, the study sample 
was composed by women with sporadic and familial BC. 
From the total of 76 cases with FHIT LOH, 30 cases were 
carriers of BRCA2 999de15 germ line mutation. And be-
sides, it was observed a significant correlation between 
FHIT LOH and ER and PR negativity, which are also 
parameters associated to familial BC. Our study included 
167 informative cases. We intend to analyze if the LOH at 
the FHIT gene alone could impact on clinical pathologic 
characteristics and patients survival, considering a large 
sample of exclusively sporadic BC. After multivariate 
analysis our results evidenced nothing but two well-estab-
lished independent prognostic factors for BC: TNM stage 
and disease relapse. The FHIT LOH had no significant 
association with patients’ prognoses. This could be due 
to the fact that we used only one microsatellite marker. 
Nevertheless we have chosen an accurate marker accord-
ing to previous studies and the frequency of 31% of FHIT 
DOI: https://doi.org/10.30564/jor.v3i2.3632
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LOH we detected is within the range published before. 
According to our data, LOH at the FHIT gene is not re-
lated to clinical parameters for BC. So we can infer that 
other mechanisms could explain the association between 
low levels of Fhit protein and adverse biological behavior 
demonstrated in earlier researches [15-17,26].
Yang et al. [27] have tested the two-hit theory for FHIT 
complete inactivation and found a high index of concord-
ance among LOH (first-hit), promoter hypermethylation 
(second-hit) and absent Fhit protein expression in BC 
samples. The authors reported that the FHIT hypermeth-
ylation was an event much more frequent than LOH in 
BC. These findings empower the model of biallelic inac-
tivation requirement for the whole silencing of a tumor 
suppressor gene [28]. And, at the same time, it raises the 
hypothesis that demethylating-therapy could play a role 
for such tumors.
Other possibilities cannot be ruled out, as splicing ab-
normalities [13,29] and coexistent allelic losses at chromo-
some 3p. [30] Also FHIT point mutations, though rarely can 
occur, and influence on the gene transcripts [7].
Knowledge about the FHIT function and role in breast 
tumors are still not fully explained. Considering that alter-
ations in Fhit protein may have implications in mammary 
carcinogenesis, further studies are needed to explore the 
mechanisms whereby these changes occur. 
5. Conclusions
Our results show that FHIT LOH by itself is not a 
prognostic factor for BC. However efforts must remain to 
elucidate the functional significance of LOH at FHIT gene 
and its connection to BC.
The variable frequencies of LOH found in other studies 
can be explained by some factors, such as different meth-
odologies in which other studies evaluate LOH in samples 
in paraffin blocks. In different types of samplings, such as 
sporadic breast cancer, hereditary breast cancer, bilateral 
breast cancer, benign breast disorders compared to ma-
lignant. Another relevant factor is that some studies have 
evaluated other microsatellite markers that may have been 
a limitation of our study. We also hypothesized that dif-
ferent results could be found if the study population were 
hereditary breast cancer. As a future prospect we intend to 
evaluate FHIT gene methylation and protein expression.
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Age, years 55.95±11.96 56.24±11.42 55.29±13.170 <0.586
Tumour size, cm 2.93±2.24 2.69±1.83 3.48±2.910 <0.220
Tumour grade <0.808
I 18 (10.8) 13 (11.3) 05 (9.6)0
II 83 (49.7) 55 (47.8) 28 (53.8)
III 66 (39.5) 47 (40.9) 19 (36.5)
TNM stage <0.053
I-II 109 (65.3)0 81 (70.4) 028 (53.8)
III-IV 58 (34.7) 34 (29.6) 024 (46.2)
Vascular invasion <0.228
No 77 (51.3) 55 (55.0) 22 (44.0)
Yes 73 (48.7) 45 (45.0) 28 (56.0)
Molecular phenotype <0.988
Luminal A 51 (31.1) 31 (27.4) 20 (39.2)
Luminal B 73 (44.5) 57 (50.4) 16 (31.4)
HER2 10 (6.1)0 06 (5.3)0 04 (7.8)0
Triple negative 30 (18.3) 19 (16.8) 11 (21.6)
Estrogenic receptor 0.333
Negative 40 (24.0) 25 (21.7) 15 (28.8) <
Positive 127 (76.0)0 90 (78.3) 37 (71.2)
Ki67 <0.220
14%< 68 (43.9) 43 (40.2) 25 (52.1)
>14% 87 (56.1) 64 (59.8) 23 (47.9)
Neoadjuvant chemotherapy <0.715
No 117 (70.1)0 82 (71.3) 35 (67.3)
Yes 50 (29.9) 33 (28.7) 17 (32.7)
Note: Data were presented as No. (%) or mean ± SD. 
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